Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 17/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | LGMN | Q99538 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16054143 | 0.90 | LMNA (0.61) | LMNAMAPTRECQLSIRT6PKM | |
| SCHEMBL5445416 | 0.88 | MAPT (0.65) | LMNAMAPTRECQLSIRT6PKM | |
| SCHEMBL29843690 | 0.88 | MAPT (0.65) | LMNAMAPTRECQLSIRT6PKM | |
| Hydrochloric Acid SCHEMBL28515977 | 0.87 | MAPT (0.63) | LMNAMAPTRECQLSIRT6PKM | |
| SCHEMBL26423365 | 0.86 | LMNA (0.57) | LMNAMAPTRECQLSIRT6PKM | |
| SCHEMBL3109069 | 0.86 | LMNA (1.00) | LMNAMAPTRECQLSIRT6ALDH1A1 | |
| SCHEMBL30059159 | 0.86 | LMNA (1.00) | LMNAMAPTRECQLSIRT6ALDH1A1 | |
| SCHEMBL25877527 | 0.86 | LMNA (0.94) | LMNAMAPTRECQLSIRT6ALDH1A1 | |
| SCHEMBL18036523 | 0.86 | MAPT (0.75) | LMNAMAPTPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL8074050 | 0.84 | LMNA (0.97) | LMNAMAPTRECQLSIRT6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| WO-2025099451-A1 | NEW COMPOUNDS AND METHODS | Transition Bio Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| CN-116217551-B | Substituted indazole or azaindazole compounds and application thereof | 河南中医药大学 | 2024-07-30 | — | — | CN | disclosed |
| US-20240199625-A1 | BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING SAME, AND APPLICATION THEREOF | HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| CN-117886798-A | Substituted benzimidazoles and use thereof | 河南中医药大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-4317143-A1 | BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING SAME, AND APPLICATION THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117062809-A | Bicyclic heterocyclic FGFR4 inhibitors, pharmaceutical compositions and formulations comprising the same and uses thereof | 杭州普洛药物研究院有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116217551-A | Substituted indazole or azaindazole compounds and application thereof | 河南中医药大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-111032643-B | Quinolinone compounds | 詹森药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002018383-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-20010052156-A1 | DYES | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 2001-12-20 | — | — | US | disclosed |
| US-20010005914-A1 | OXIDATION DYES | ANDREAS J. BITTNER | 2001-07-05 | — | — | US | disclosed |
| EP-0912160-A2 | OXIDATION DYES | Hans Schwarzkopf GmbH & Co. KG (DE) | 1999-05-06 | — | — | EP | disclosed |
| EP-0910332-A2 | DYES | Hans Schwarzkopf GmbH & Co. KG (DE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998001105-A2 | DYES | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998001106-A2 | OXIDATION DYES | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010052156-A1 | DYES | KRT18, OPRD1, HTR1D | LMNA 2827/4885MAPT 4151/4885RECQL 3478/4885 |
| US-20010005914-A1 | OXIDATION DYES | AOC1, CBR3, KRT18 | LMNA 1692/4885MAPT 3633/4885RECQL 2228/4885 |
| US-20240199625-A1 | BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING SAME, AND APPLICATION THEREOF | FGFR4, FGFR3, FGFR1 | LMNA 3847/4885MAPT 2742/4885RECQL 1971/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | LMNA 834/4885MAPT 4502/4885RECQL 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.